UCB SA (UCB)’s biggest shareholder says the Belgian drugmaker isn’t for sale, even as analysts say medicines for rheumatoid arthritis and epilepsy make the company an attractive takeover target.
The Janssen family, which owns 36 percent of Brussels-based UCB through holding company Financiere de Tubize SA, has no plans to sell the stake, said Marc Van Steenvoort, a Tubize spokesman. UCB’s market value of 9.1 billion euros ($12.3 billion) makes Tubize’s stake worth about 3.3 billion euros.
Help employers find you! Check out all the jobs and post your resume.
